Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
-
Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
-
Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
-
PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
-
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
-
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...